Another pilot study by Paolo Basile et al. showed that six months of treatment with GLP-1 RA (dulaglutide or semaglutide) led to an improvement in GLS in subjects with T2DM and with a high/very high risk of atherosclerotic cardiovascular disease (ASCVD) or with established ASCVD [28]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.